Uneven breaking of a tablet may result in significant fluctuations in the administered dose. This may be clinically significant for drugs with a narrow therapeutic range,1 such as warfarin or digoxin. For many drugs, however, especially those with long half-lives and/or a wide therapeutic range, dose fluctuations are unlikely to be clinically significant.
Removing tablets from foil packaging or exposing uncoated tablet surfaces may increase the rate of degradation of the active drug. This has important ramifications as the patient may get a lower than intended dose and adverse effects may be increased by degradation products. The tablet dissolution rate and absorption characteristics may also be affected when tablets are split.2 This applies particularly to coated and controlled-release tablets. While the cumulative dissolution may be similar between whole and halved tablets the initial rate of dissolution may be increased with unpredictable clinical consequences. Some sustained-release (extended duration) formulations can be halved without affecting their extended-release characteristics (e.g. isosorbide mononitrate, bupropion) while others cannot (e.g. felodipine (Agon SR), tramadol (Tramal SR)) and it is therefore important to check the product information of each specific brand if splitting tablets is considered. Many tablets are coated to mask the taste of the drug. Splitting may therefore expose a drug's taste. Table 1 provides a general guide, with limited examples, as to which tablets may not be suitable for splitting.
Tablets that are scored are usually considered by the manufacturer to be suitable for division and the majority of tablets are made this way. Not all tablets, however, are suitable for splitting and this should be considered when the recommendation to split the tablet is made. The degree of inaccuracy may be associated with tablet size, shape and type of scoring (Table 2). Some tablets, even with a score line, may not break easily into two pieces of equal size.1 The length of time that drugs remain stable after splitting also needs to be considered as the drug may not be stable when the cut surface is exposed to air for even short periods (up to 24 hours) let alone tablets pre-cut for doses a week or more in advance. This may be of importance if a carer, district nurse or pharmacist has to split tablets in advance for patients unable to manage the task.
The storage of split tablets is not well discussed in the literature. Anecdotal evidence suggests that many patients, or their carer, nurse or pharmacist, split a number of tablets in advance. Patients store split tablets in bottles that previously contained the same medication, different medication or some other substance, or in the same bottle as whole tablets or in a dosage administration aid. Issues of concern relate to labelling of storage containers and the time that split tablets are exposed to air and light before use with the possible detrimental effect on stability. For example the instability of soluble aspirin limits the usefulness of the unused half of a split tablet. If only half the tablet is taken the unused half should be immediately discarded.
Table 1 Types of tablets that are not recommended to be split
Types of tablets that should not be split
|
Examples (not a complete list)
|
Unscored tablets
|
d-penicillamine (D-Penamine) acarbose (Glucobay 50 mg) metformin (Diaformin 850) tiludronate (Skelid)
|
Unusually thick or oddly shaped tablets
|
alendronate 40 mg (Fosamax 40 mg) finasteride (Proscar 5 mg) fosinapril (Monopril) amiloride (Midamor)
|
Film-coated tablets
|
nifedipine (Nifecard) donepezil (Aricept) tamoxifen (Nolvadex) azathioprine (Imuran 25 mg)
|
Enteric-coated tablets
|
valproate (Epilim 200 mg, Epilim 500 mg) diclofenac (Voltaren) mesalazine (Mesasal) pantoprazole (Somac)
|
Some time-release and extended-release tablets
|
felodipine (Agon SR) cefaclor CD 375 mg (all brands) potassium chloride (KSR, Slow K, Span K) tramadol (Tramal SR)
|
Table 2 Factors contributing to increased inaccuracy of tablet splitting
Tablet factor contributing to inaccuracy
|
Examples (not a complete list)
|
Small size
|
digoxin (Lanoxin-PG) temazepam (Temaze)
|
Irregular shape
|
fosinapril (Monopril) lamotrigine (Lamictal) alendronate (Fosamax) auranofin (Ridaura)
|
Scored on one side only
|
alprazolam (Kalma) benztropine (Cogentin) selegiline (Eldepryl) clozapine (Clozaril)
|